These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21285145)

  • 21. Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
    Neuhausen SL; Brummel S; Ding YC; Singer CF; Pfeiler G; Lynch HT; Nathanson KL; Rebbeck TR; Garber JE; Couch F; Weitzel J; Narod SA; Ganz PA; Daly MB; Godwin AK; Isaacs C; Olopade OI; Tomlinson G; Rubinstein WS; Tung N; Blum JL; Gillen DL
    Breast Cancer Res; 2009; 11(5):R76. PubMed ID: 19843326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
    Engel C; Versmold B; Wappenschmidt B; Simard J; Easton DF; Peock S; Cook M; Oliver C; Frost D; Mayes R; Evans DG; Eeles R; Paterson J; Brewer C; ; McGuffog L; Antoniou AC; Stoppa-Lyonnet D; Sinilnikova OM; Barjhoux L; Frenay M; Michel C; Leroux D; Dreyfus H; Toulas C; Gladieff L; Uhrhammer N; Bignon YJ; Meindl A; Arnold N; Varon-Mateeva R; Niederacher D; Preisler-Adams S; Kast K; Deissler H; Sutter C; Gadzicki D; Chenevix-Trench G; Spurdle AB; Chen X; Beesley J; ; Olsson H; Kristoffersson U; Ehrencrona H; Liljegren A; ; van der Luijt RB; van Os TA; van Leeuwen FE; ; Domchek SM; Rebbeck TR; Nathanson KL; Osorio A; Ramón y Cajal T; Konstantopoulou I; Benítez J; Friedman E; Kaufman B; Laitman Y; Mai PL; Greene MH; Nevanlinna H; Aittomäki K; Szabo CI; Caldes T; Couch FJ; Andrulis IL; Godwin AK; Hamann U; Schmutzler RK;
    Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2859-68. PubMed ID: 20978178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
    Hughes DJ; Ginolhac SM; Coupier I; Barjhoux L; Gaborieau V; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Sobol H; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Yannoukakos D; Mazoyer S; Lynch HT; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Int J Cancer; 2005 Nov; 117(2):230-3. PubMed ID: 15900600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
    Stevens KN; Wang X; Fredericksen Z; Pankratz VS; Greene MH; Andrulis IL; Thomassen M; Caligo M; ; Nathanson KL; Jakubowska A; Osorio A; Hamann U; Godwin AK; Stoppa-Lyonnet D; Southey M; Buys SS; Singer CF; Hansen TV; Arason A; Offit K; Piedmonte M; Montagna M; Imyanitov E; Tihomirova L; Sucheston L; Beattie M; ; ; Neuhausen SL; ; Szabo CI; ; Simard J; Spurdle AB; Healey S; Chen X; Rebbeck TR; Easton DF; Chenevix-Trench G; Antoniou AC; Couch FJ
    Breast Cancer Res Treat; 2012 Nov; 136(1):295-302. PubMed ID: 23011509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
    Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
    J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    Vigorito E; Kuchenbaecker KB; Beesley J; Adlard J; Agnarsson BA; Andrulis IL; Arun BK; Barjhoux L; Belotti M; Benitez J; Berger A; Bojesen A; Bonanni B; Brewer C; Caldes T; Caligo MA; Campbell I; Chan SB; Claes KB; Cohn DE; Cook J; Daly MB; Damiola F; Davidson R; Pauw Ad; Delnatte C; Diez O; Domchek SM; Dumont M; Durda K; Dworniczak B; Easton DF; Eccles D; Edwinsdotter Ardnor C; Eeles R; Ejlertsen B; Ellis S; Evans DG; Feliubadalo L; Fostira F; Foulkes WD; Friedman E; Frost D; Gaddam P; Ganz PA; Garber J; Garcia-Barberan V; Gauthier-Villars M; Gehrig A; Gerdes AM; Giraud S; Godwin AK; Goldgar DE; Hake CR; Hansen TV; Healey S; Hodgson S; Hogervorst FB; Houdayer C; Hulick PJ; Imyanitov EN; Isaacs C; Izatt L; Izquierdo A; Jacobs L; Jakubowska A; Janavicius R; Jaworska-Bieniek K; Jensen UB; John EM; Vijai J; Karlan BY; Kast K; ; Khan S; Kwong A; Laitman Y; Lester J; Lesueur F; Liljegren A; Lubinski J; Mai PL; Manoukian S; Mazoyer S; Meindl A; Mensenkamp AR; Montagna M; Nathanson KL; Neuhausen SL; Nevanlinna H; Niederacher D; Olah E; Olopade OI; Ong KR; Osorio A; Park SK; Paulsson-Karlsson Y; Pedersen IS; Peissel B; Peterlongo P; Pfeiler G; Phelan CM; Piedmonte M; Poppe B; Pujana MA; Radice P; Rennert G; Rodriguez GC; Rookus MA; Ross EA; Schmutzler RK; Simard J; Singer CF; Slavin TP; Soucy P; Southey M; Steinemann D; Stoppa-Lyonnet D; Sukiennicki G; Sutter C; Szabo CI; Tea MK; Teixeira MR; Teo SH; Terry MB; Thomassen M; Tibiletti MG; Tihomirova L; Tognazzo S; van Rensburg EJ; Varesco L; Varon-Mateeva R; Vratimos A; Weitzel JN; McGuffog L; Kirk J; Toland AE; Hamann U; Lindor N; Ramus SJ; Greene MH; Couch FJ; Offit K; Pharoah PD; Chenevix-Trench G; Antoniou AC
    PLoS One; 2016; 11(7):e0158801. PubMed ID: 27463617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
    Rebbeck TR; Kauff ND; Domchek SM
    J Natl Cancer Inst; 2009 Jan; 101(2):80-7. PubMed ID: 19141781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
    Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.
    Milne RL; Antoniou AC
    Endocr Relat Cancer; 2016 Oct; 23(10):T69-84. PubMed ID: 27528622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.